Pure Global AI
NCT06391645Not yet recruiting

Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis

Beijing Tiantan HospitalPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Amyotrophic Lateral Sclerosis
Drug/Device/Intervention
Nerve Growth Factor
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing Tiantan Hospital
Timeline & enrollment
Phase
Phase 2/3
Start date
May 01, 2024
End date
Dec 01, 2026
Enrollment
60 participants
Primary outcome

Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)

Summary

Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases,
 with most patients dying from respiratory failure 3-5 years after the onset. The purpose of
 this study is to explore the efficacy and safety of nerve growth factor (NGF) encapsulated
 with 2-methacryloyloxyethyl phosphorylcholine (MPC) nanocapsules in the treatment of ALS
 patients.

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06391645
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06391645 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Beijing Tiantan Hospital and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.